RPRX — Royalty Pharma Share News
0.000.00%
Last trade - 00:00- $36.72bn
- $47.80bn
- $2.38bn
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)
Teva's immune disorder drug meets main goal in mid-stage trial
Brief: Royalty Pharma And Zealand Pharma Enter Into Rusfertide Funding Agreement For $100 Million
Royalty Pharma PLC reports results for the quarter ended June 30 - Earnings Summary
Brief: Royalty Pharma Reports Second Quarter 2026 Results
Royalty Pharma Q2 adjusted EBITDA beats estimates
Brief: Neurimmune Sells A Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma
Brief: Royalty Pharma - Enters Revolving Credit Agreement On May 22, 2026
Royalty Pharma Q1 adjusted EBITDA misses analyst estimates
Zymeworks rises after naming new CFO
Zymeworks rises after naming new CFO
Brief: Royalty Pharma Announces Research And Development Funding Collaboration For Chronic Immune-Mediated Diseases
Royalty Pharma and J&J partner to develop autoimmune treatment
Brief: Zymeworks And Royalty Pharma Enter Into $250 Million Royalty-Backed Note Financing
Royalty Pharma Q4 adjusted EBITDA beats analyst expectations
Brief: Royalty Pharma To Announce Fourth Quarter And Full Year 2025 Financial Results On February 11, 2026